Mendus Q4 2022 - A clearer path forward
2023-02-17 14:59:00
Redeye comments on Mendus’ Q4 2022 report, with the company presenting a way forward for lead candidate vididencel (formerly DCP-001). Further, we believe the company will need to find a more sustainable financing solution than its current convertible debt arrangement with Negma Group. We adjust our model for the company’s new development plans and current resource constraints.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/